Baltimore, September 11, 2006
AuRx announces the termination of its technology license agreement
with Landsteiner Scientific of Mexico City, Mexico
AuRx has successfully terminated its license with Landsteiner Scientific.
AuRx entered into an agreement with Landsteiner in April of 2004,
in which Landsteiner would be responsible for further Phase III
testing, plant construction and commercialization of the AuRx therapy
for genital herpes.
The license was terminated in December, 2005, by AuRx due to Landsteiner's
failure to make certain payments and to move forward with the commercialization.
Landsteiner agreed to AuRx's right to termination for cause on August
AuRx is currently seeking other partners who have the ability to
commercialize its therapy for genital herpes as well as equity investors
who may provide funds for commercialization.
Genital herpes is a sexually transmitted disease that affects 17%
of the U.S. population (approximately 50 million persons). Outbreaks
of genital herpes lesions generally last for 7 days, however, other
signs or symptoms often occur when lesions are not present. These
include pain, itching, dysuria, and burning in the genital area.
Genital herpes is also known to accelerate the progression of HIV
to AIDS. No effective therapy exists for the treatment of genital
herpes, however, drugs such as acyclovir and valacyclovir do decrease
the length of time lesions are present and extend the time between
occurrence of lesions. No effect on other signs and symptoms has
In earlier studies, the AuRx therapy was shown to be safe and decrease
the occurrence of lesions by 86%. The AuRx therapy also effectively
prevented all signs and symptoms in 44% of patients at one year
with a series of two inoculations over a period of two years. Relative
to earlier years, the patients receiving the inoculations who did
not have complete immunity, nevertheless, had a reduction in patient
episodes, including all signs and symptoms of 70%. This effectiveness
occurred in severely afflicted patients as most studies on acyclovir
and valacyclovir used patients with an average of 5 episodes per
year, whereas the AuRx trial used patients with an average of 9
episodes per year.
For Additional Information Contact:
Gary J. Calton, President,
5331 Landing Road
Elkridge, Maryland 21075